Core Insights - Eli Lilly's EBGLYSS (lebrikizumab-lbkz) shows up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis, achieving significant skin improvement and itch relief [1][4]. Efficacy Results - In the ADlong Phase 3b study, 94% of patients achieved a 75% reduction in eczema severity (EASI-75), 75% achieved near-complete skin clearance (EASI-90), and 68% were rated as "clear" or "almost clear" (IGA 0,1) [2]. - 78% of patients reported significant itch relief (Pruritus NRS 4), and 80% achieved durable results without the need for topical corticosteroids [1][2]. Safety Profile - The safety of EBGLYSS in the first year of the ADlong study was consistent with known profiles, with no new safety signals observed. Most adverse events were mild or moderate, including conjunctivitis (6.9%) and injection-site reactions (0.6%) [3][4]. Ongoing Studies - The ADlong study is ongoing, with additional treatment planned for another year. Previous long-term results have been reinforced, showing less than one flare per patient per year with EBGLYSS used as monotherapy [4][20]. Company Strategy - Eli Lilly is committed to advancing dermatology care and investing in next-generation immunology innovations, including therapies for psoriatic disease and hidradenitis suppurativa [4][5]. Market Position - Lilly holds exclusive rights for the development and commercialization of EBGLYSS in the U.S. and other regions outside Europe, while Almirall has licensed rights for European dermatology indications [5][8]. Treatment Administration - EBGLYSS is administered as a monthly injection after an initial dosing phase, with a recommended starting dose of 500 mg followed by 250 mg every two weeks until Week 16, then transitioning to monthly maintenance [9][10].

Core Insights - Eli Lilly's EBGLYSS has shown significant long-term efficacy in treating moderate-to-severe atopic dermatitis, with 50% of patients achieving complete skin clearance and 87% achieving almost-clear skin after three years of treatment [1][20][24] - The drug was approved in the U.S. as a first-line monotherapy biologic treatment option in September 2024, following topical therapies [1][20] - EBGLYSS is an interleukin-13 (IL-13) inhibitor that effectively targets the inflammatory processes associated with atopic dermatitis [1][19] Efficacy and Study Results - In the ADjoin long-term extension study, 50% of patients receiving once-monthly maintenance doses achieved complete skin clearance (EASI 100 or IGA 0) at three years, while 87% maintained almost-clear skin (EASI 90) [1][5] - Over 83% of Week 16 responders did not require concomitant therapies such as topical corticosteroids during the study [1] - Additional studies (ADmirable and ADapt) demonstrated significant improvements in itch, skin pain, and sleep loss due to itch among diverse patient groups [1][26][27] Safety Profile - The safety profile of EBGLYSS in recent studies was consistent with previous Phase 3 studies, with no new safety signals reported [2] - Most adverse events were mild or moderate, with conjunctivitis and injection-site reactions being the most common treatment-related side effects [2] Market Position and Development - EBGLYSS is the only first-line biologic treatment option for patients with moderate-to-severe atopic dermatitis uncontrolled by topical therapies, offering a once-monthly maintenance dosing regimen [3][20] - Eli Lilly has exclusive rights for the development and commercialization of EBGLYSS in the U.S. and other regions outside Europe, while Almirall holds rights for European dermatology indications [3][20] Future Directions - Further data from the ADmirable study, focusing on patients with skin of color, is expected to be shared in 2025, indicating ongoing commitment to diverse patient populations [19][26]